The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.
Ongoing clinical trials for diarrhea: Actively recruiting
Irritable bowel syndrome
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
|Description of study:||
We are doing this research study to find out if a new drug, JNJ-27018966, can help people with irritable bowel syndrome with diarrhea (IBS-d). People with IBS-d have abdominal discomfort or pain along with frequent diarrhea. We also want to find out if JNJ-27018966 is safe to take without causing too many side effects. The primary objectives of this study are:
The secondary objective of this study is to further evaluate the treatment effect of JNJ- 27018966 relative to placebo based on patient reports of IBS-d symptoms (abdominal pain, abdominal bloating, stool consistency, global symptom scores, adequate relief), bowel functioning, and quality of life.
|Basic eligibility criteria:||
1. Between the ages of 18-80
Shahar Castel; 617-726-0196